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Practical Implications of Differential Discounting of Costs and Health
Effects in Cost-Effectiveness AnalysisRecently in this journal, O’Mahony and colleagues [1] published an
article on the practical implications of differential discounting in
the analysis of the cost-effectiveness of human papillomavirus
(HPV) vaccination in the Netherlands. In particular, they show a
fall in the cost-effectiveness ratio with the inclusion of additional
cohorts under differential discounting. We disagree with some
arguments and suggestions made by the authors and will list these
below with adjacent argumentation. We start with briefly summa-
rizing the state of the art on discounting in health economics and
for vaccines’ health economics in particular.
In general, in health economics, discounting of health out-
comes has been heavily debated already for various decades. The
practical consensus often is to discount health outcomes with an
equal rate compared with that of costs. However, it has been ar-
gued that health effects should be discounted with a lower rate
than costs, given the expected increase in the value of health over
time. Furthermore, differences in the pace at which economies
and life expectancies grow pose an argument for differential dis-
counting. These arguments have been substantiated with spe-
ific methodological frameworks [2,3]. However, consensus on
differential discounting certainly does not yet exist [4,5], and
currently only in the Netherlands and Belgium differential dis-
count rates are used for future costs and health outcomes (in
particular, 3– 4% for costs and 1.5% for health effects). Cost-
effectiveness analyses in the Netherlands that have contributed
to health-care policy decisions recently have consistently used
these specific percentages for discounting, including those
analyses that were directed at the cost-effectiveness of HPV
vaccination [6]. In the area of vaccines, discounting impacts
relatively strong as compared with, for example, classical phar-
maceuticals [7]. Previously, we have advocated differential dis-
counting in particular for HPV vaccination [8,9].
O’Mahony et al. [1] show that the incremental cost-effective-
ness ratio (ICER) for HPV vaccination decreases if differential dis-
counting is applied with an increasing number of annual vacci-
nated cohorts analyzed; that is, going from single cohort, through
10 and 20, to 30 cohorts. In their wordings, they label the choice of
how many cohorts to include in the model as “arbitrary variation
in study specification” and subsequently the related outcomes as
“arbitrary variation in results.” With differential discounting, the
ICER decreases in their hypothetical calculations from almost
€30,000, through €27,000 (10 cohorts) and €24,000 (20 cohorts), to
€22,000 per quality- adjusted life-year if 30 cohorts are analyzed.
We would argue that the choice of the number of generations to
include in the model is far from arbitrary, as is the corresponding
outcome. In particular, the number of cohorts included in the
model should directly reflect the envisioned time horizon for the
implementation of the vaccination. As generally a vaccination
program is not foreseen for 1 year only, inclusion of multicohorts
is an adequate approach. The exact number of cohorts is to bediscussed; however, rather than being arbitrary it should reflect a
valid idea on the minimum period for the vaccination program to
be in place. That many researchers do choose a single-cohort
model for analysis can easily be motivated by the fact that 1) a
model as least complex as possible should always be strived for
and 2) this would always represent a conservative approach, given
the downward slope of the ICER as a function of the number of
cohorts included.
If specification of the time horizon for intervention upfront is
not desired or possible in a multicohort model, the following rea-
soning might be considered. Notably, the authors consistently dis-
count costs and effects to the first year; that is, the year in which
the first cohort is vaccinated. It might, however, be argued that the
benefits for a particular cohort should be discounted to the mo-
ment the intervention took place in this specific cohort, which
would result in identical ICERs for each subsequent cohort. Corre-
spondingly and consistently based on the theoretical basis of
differential discounting, it might be argued that the willing-
ness-to-pay threshold increases for subsequent cohorts. In par-
ticular, because of the increasing value of health over time, the
willingness-to-pay threshold increases, rendering the constant
ICERs more cost-effective year by year. We argue that in judging
the ICERs of subsequent cohorts one should take this change in
the willingness-to-pay threshold into account. So, potentially it
is possible that because of the increasing value of health, an
intervention might not be cost-effective for the current cohort,
while the intervention will become cost-effective for future co-
horts. This is fully in line with the rationale behind differential
discounting.
Finally, we would like to briefly comment on the model used by
the authors. In particular, a static multicohort model was used to
estimate the epidemiological and economical consequences of
HPV vaccination. Obviously, in the present study, a multicohort
model offers no advantages over a single-cohort model, as illus-
trated by the similar cost-effectiveness ratios for the equal-dis-
counting options in the single cohort’s, 10 cohorts’, 20 cohorts’,
and 30 cohorts’ analyses. This does make the analysis a bit artifi-
cial, although the advantage is that other factors that might influ-
ence outcomes all remain the same. Yet, it has been argued that
for interventions against infectious diseases, the use of dynamic
modeling approaches is preferable, as with such models herd-
immunity benefits can be explicitly taken into account [10]. Nota-
bly, models for HPV vaccination should consider herd-immunity
benefits through the indirect protection of nonvaccinated individ-
uals, and the size of this effect will differ between different vacci-
nated cohorts. In such a dynamic model consequently the ICERs
will change from year to year even under equal discounting since
herd-immunity is dependent on the changing proportion of vac-
cinated individuals. So, besides changes in cost-effectiveness over
various cohorts due to discounting, crucial changes in cost-effec-
1174 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 7 3 – 1 1 7 5tiveness will become apparent because of crucial changes in vac-
cination coverage and epidemiology that quickly overrule varia-
tions due to discounting.
Acknowledgement
This work benefited from the Dutch ZonMw grant 152002008. Dr.
Cornelis Boersma is currently employed with GSK (Zeist, Nether-
lands) and is visiting researcher at the University of Groningen;
this work was performed in the framework of his visiting re-
searchship.
Tjalke A. Westra, MSc
Department of Medical Microbiology,
Molecular Virology Section,
University Medical Center Groningen,
University of Groningen,
Groningen, The Netherlands
Mehraj B.Y. Parouty, MSc
Unit of PharmacoEpidemiology & PharmacoEconomics (PE2),
Department of Pharmacy,
University of Groningen, Groningen,
The Netherlands
Jan C. Wilschut, PhD
Department of Medical Microbiology,
Molecular Virology Section,
University Medical Center Groningen,
University of Groningen,
Groningen, The Netherlands
Cornelis Boersma, PhD
Unit of PharmacoEpidemiology & PharmacoEconomics (PE2),
Department of Pharmacy,
University of Groningen,
Groningen,
The Netherlands
cal implications of differential discounting is important. OurMaarten J. Postma, PhD
Unit of PharmacoEpidemiology & PharmacoEconomics (PE2),
Department of Pharmacy,
and Department of Epidemiology,
University Medical Center Groningen,
University of Groningen,
Groningen, The Netherlands
1098-3015/$36.00 – see front matter
Copyright © 2011, International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).
Published by Elsevier Inc.
doi:10.1016/j.jval.2011.07.013
R E F E R E N C E S
[1] O’Mahony JF, de Kok IM, van Rosmalen J, Habbema JD, Brouwer W, van
Ballegooijen M. Practical implications of differential discounting in
cost-effectiveness analyses with varying numbers of cohorts. Value
Health 2011;14:438–42.
[2] Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential
discounting of costs and health effects in cost effectiveness analyses.
BMJ 2005;331:446–8.
[3] Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in
economic evaluations: stepping forward towards optimal decision
rules. Health Econ 2007;16:307–17.
[4] Claxton K, Sculpher M, Culyer A, et al. Discounting and cost-
effectiveness in NICE—stepping back to sort out a confusion. Health
Econ 2006;15:1–4.
[5] Claxton K, Paulden M, Gravelle H, et al. Discounting and decision
making in the economic evaluation of health-care technologies.
Health Econ 2011;20:2–15.
[6] Dutch Health Council. Vaccination against Cervical Cancer. The
Hague: Health Council; 2008. Available at: http://www.
gezondheidsraad.nl/en/publications/vaccination-against-cervical-
cancer-0 [Accessed September 2010].
[7] Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines
warrant a different approach? Lancet Infect Dis 2008;8:727–33.
[8] Postma MJ. Cost-effectiveness analysis of human pappilomavirus
(HPV) vaccination in the Netherlands: recent publication reinforces
favorable cost-effectiveness despite misleading conclusion. Vaccine
2010;28:873–4.
[9] Rozenbaum MH, Boersma C. Cost-effectiveness analysis of human
papillomavirus vaccination in the Netherlands. J Natl Cancer Inst
2010;102:358–9.[10] Jit M, Brisson M. Modelling the epidemiology of infectious diseases for
decision analysis: a primer. Pharmacoeconomics 2011;29:371–86.Practical Implications of Differential Discounting of Costs and Health
Effects in Cost-Effectiveness AnalysisWe welcome Westra et al.’s comments on our recent article that
addressed the influence of the number of future cohorts on
cost-effectiveness estimates under differential discounting.
Their comments usefully illustrate some of the unresolved
questions regarding the correct implementation of differential
discounting.
Differential discounting is already recommended practice in
The Netherlands and Belgium and is also being used in a number
of other countries. The National Institute for Health and Clinical
Excellence in England and Wales recently recommended that
differential discounting be applied in a sensitivity analysis in
certain circumstances [1]. Therefore, understanding the practi-article intended to further develop that understanding, not op-
pose differential discounting.
Westra et al. contend that variation in cost-effectiveness esti-
mates due to the differences between studies in the numbers of
cohorts modeled is not arbitrary because the numbers of cohorts
modeled are not arbitrary but determined by the time horizon for
the implementation of the intervention. We did not claim in our
article that the number of cohorts modeled is arbitrary in any
general sense. We contend that if there is no clear and consistently
applied understanding of the appropriate number of cohorts to
include in CEAs then the actual number of cohorts modeled may
vary arbitrarily between studies. This is the situation as we see it
at present, evidenced by the large variation in the numbers of
